Silas Inman

Chief Brand Officer @MJHLifeSciences focused on innovative, audience-driven results @OncLive @MedEconomics @AJMC_Journal @Pharmacy_Times @MDMagazine plus more

[Silas Inman @SilasInman]

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC https://t.co/tffC46kgav

[Silas Inman @SilasInman]

AZ is joining the GLP1 market: Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data https://t.co/Mem4KIPz3B

[Silas Inman @SilasInman]

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer https://t.co/AYs8tgXwVw

[Silas Inman @SilasInman]

A near miss in colorectal cancer. #ASCO26: JCOG’s EPISODE-III found low-dose aspirin fell just short on DFS in unselected stage III CRC (HR 0.84, p=0.099). The +3.4% 3Y-DFS signal and RFS trend (HR 0.87) suggest the answer may live in the biomarkers. PI3K/PIK3CA analyses ongoing.

[Silas Inman @SilasInman]

Oral daraxonrasib hit all primary and key secondary endpoints in the phase 3 RASolute 302 trial for pancreatic cancer, nearly doubling median OS (13.2 vs 6.7 mo) and cutting risk of death 60% (HR 0.40) vs chemo. A potential new standard of care. #ASCO26 https://t.co/Ck7SGNbhvO

[Silas Inman @SilasInman]

Giredestrant Cuts Recurrence Risk Across Menopausal Status in ER+/HER2- Early Breast Cancer https://t.co/eqJUawyxbw

[Silas Inman @SilasInman]

Puxitatug Samrotecan Elicits High Response Rate in Select Endometrial Cancers https://t.co/GEQaEEj0Pb #ASCO26

[Silas Inman @SilasInman]

More info here https://t.co/IrFDRcmxqZ

[Silas Inman @SilasInman]

LY4052031 shows promising activity in metastatic urothelial cancer: 33% ORR, 75% DCR and 7.4-month median DoR in EV-pretreated patients. Nectin-4 stays a key target even after EV progression, with CYP2D6 genotyping guiding tolerability. #ASCO26

[Silas Inman @SilasInman]

More info on the study here https://t.co/GgNEn3NjyM

[Silas Inman @SilasInman]

Phase 3 OptiTROP-Lung05: sac-TMT + pembrolizumab is the first ADC combo to show significant PFS benefit as first-line treatment for PD-L1+ advanced NSCLC vs pembrolizumab alone. Median PFS not reached vs 5.7 mo (HR 0.35, p<0.0001), with a manageable safety profile. #ASCO26

[Nicholas Hornstein @GIMedOnc]

#ASCO26
5-FU bolus, leucovorin and DPYD… what are people actually doing in practice?

We’re running a quick 1–2 min survey looking at real-world patterns across adjuvant + metastatic CRC.

Would appreciate input from both academic + community providers.

https://t.co/nLga01z3lT

We’ll share results back.

[Silas Inman @SilasInman]

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic TNBC https://t.co/4SBEAGf1rd

[Silas Inman @SilasInman]

Let #ASCO26 begin! Early look at some of the emerging lung cancer data from the recently released abstracts https://t.co/9L3RmQoQFj

[Silas Inman @SilasInman]

FDA Approves Baxdrostat for Uncontrolled Hypertension on Background Therapy https://t.co/fZxGmRK2u4

[Silas Inman @SilasInman]

FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer https://t.co/XHuey0u6UN

[Silas Inman @SilasInman]

FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma https://t.co/LFidCkxo6d

[Silas Inman @SilasInman]

FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma https://t.co/oc3slxV2eP

[Silas Inman @SilasInman]

FDA Green Lights Expanded Access Protocol for Daraxonrasib in Pretreated Metastatic PDAC https://t.co/tfQTWZ5Gau

[Silas Inman @SilasInman]

FDA Approves Vepdegestrant for ER+/HER2– Advanced Breast Cancer With an ESR1 Mutation https://t.co/tVVfQyHn9m